공시 • Apr 14
Hofseth BioCare ASA Publishes Clinical Trial Results of Omego Full Spectrum Omegas Hofseth BioCare ASA announced the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo. The trial showed that OmeGo increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health. The omega-3 index (O3I) assesses the level of EPA and DHA in red blood cells – a measure known to correlate well with the overall amount of omega-3 in the body. An optimal O3I level has been shown to reduce the risk of death from any cause by around 35%. Indeed, a higher O3I is associated with a reduced risk of major killers including cardiovascular and metabolic disease and cancer. Notably, OmeGo contains 2.5 times less EPA & DHA than the omega-3 supplement comparator used in this study. However, its natural food matrix significantly enhances OmeGo’s bioavailability. Hence its full spectrum profile better replicates the well-known health benefits associated with regularly eating fish. The success of this clinical study directly challenges the prevailing market assumption that higher-dose concentrated fish oils deliver greater health benefits. This represents a paradigm shift in how omega potency is viewed in the nutraceuticals market. 공시 • Dec 04
Hofseth BioCare ASA, Annual General Meeting, May 22, 2026 Hofseth BioCare ASA, Annual General Meeting, May 22, 2026. 공시 • Nov 21
Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million. Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 29.999999 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 16,666,666
Price\Range: NOK 1.8
Transaction Features: Rights Offering 공시 • Sep 10
Hofseth Biocare ASA Releases a Whitepaper Demonstrating How Its Bioactive Peptide Ingredient ProGo®? uniquely Provides Complete GLP-1 Support Hofseth Biocare ASA released a whitepaper demonstrating how its bioactive peptide ingredient ProGo®? uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®? addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profile to help build muscle; antioxidant and anti-inflammatory bioactivity to protect muscle health; inhibition of Activin A and Myostatin, negative regulators of muscle mass. ProGo®? is the only commercially available bioactive peptide health ingredient that is both a GLP-1 RA (Receptor Agonist) and has a targeted mode of action for muscle protection via inhibition of Myostatin & Activin A. A fully traceable, high-quality nutritional supplement comprised of hydrolysed peptides and collagen, it has a complete amino acid profile that includes high levels of branched chain amino acids (BCAA) - essential for muscle formation and health. ProGo®? also has a higher bioavailability than other peptides on the market, as the smaller average size of peptides makes them easier for the body to digest. 공시 • Sep 04
Hofseth BioCare ASA Appoints Paul Bruhn as Head of New Business Development Hofseth BioCare ASA announced the appointment of Paul Bruhn as Head of New Business Development. Mr. Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis Medical Nutrition and Nestle Health Science. He has been leading businesses across multiple geographies including Japan, Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and hence has an excellent overlap with corporates focused on developing the next generation of products targeting clinical nutrition and consumer healthcare. Mr. Bruhn has significant experience working within the medical nutrition, VMS and meal replacement categories, across multiple channels. 공시 • Nov 11
Hofseth BioCare ASA, Annual General Meeting, May 23, 2025 Hofseth BioCare ASA, Annual General Meeting, May 23, 2025. 공시 • Nov 09
Hofseth BioCare ASA to Report Q4, 2025 Results on Feb 13, 2026 Hofseth BioCare ASA announced that they will report Q4, 2025 results at 12:00 PM, Central European Standard Time on Feb 13, 2026 공시 • Oct 22
Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO Hofseth BioCare ASA announced that Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of the company to pursue opportunities outside of the company. 공시 • Mar 15
Hofseth BioCare ASA Announces Board Changes Hofseth BioCare ASA announced Kristin Fjellby Grung, Chair of the Board has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board. Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her services for Hofseth BioCare in this period. Appointment of a new Chair of the Board will be proposed to the Company's annual general meeting, to be held on 10 May 2024. In the interim period, Roger Hofseth will function as the Chair of the Board of Directors. 공시 • May 31
Hofseth Biocare ASA Announces the Online Publication of Its Abstract Hofseth Biocare ASA announced the online publication of its abstract titled "Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer models" (Journal of Clinical Oncology 41, 2023, supplement 16; abstract # e15186) ahead of the annual ASCO meeting in Chicago, June 2-5, 2023. This work by HBC represents the final phase of invitro research which has identified the lead peptide candidates, FT-002 and FT-005, for organoid and in vivo prostate cancer research in combination with standard of care therapy, planned to commence during H2 2023. Prostate cancer remains the most commonly diagnosed cancer in men. Whilst most cases do not shorten life expectancy, advanced prostate cancer remains largely incurable. Hormone therapy remains the cornerstone of treatment however eventually tumours find ways of overcoming treatment and start to grow and spread. One important route of tumour escape is via hijacking cellular iron metabolism. In preclinical models, including those published in the ASCO abstract, FT-002 and FT-005 have shown a consistent ability to modulate iron metabolism within tumour cells to both enhance tumour cell sensitivity to standard of care hormone therapy as well as reversing resistance to standard hormone therapy. 